Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN23 in Adult Chinese Patients With TIO
NCT05357573Phase 4Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of burosumab in tumor-induced osteomalacia (TIO), sponsored by Kyowa Kirin. Primary endpoint: Change from Baseline in mean serum phosphorus level at 48 weeks. Started Sep 2022; status: completed.
02
Drugs
burosumab
03
Conditions
tumor-induced osteomalacia (TIO)
Beyond the preview
Go deeper on NCT05357573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357573.